Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Type 2 DiabetesDiabetic NephropathyHypertensionSleep Apnea
Interventions
DEVICE

NCPAP; Nasal continuous positive airway pressure.

Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.

DEVICE

NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group

In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.

Trial Locations (1)

K1H 7W9

The Ottawa Hospital, Ottawa

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER